Early BCG-Denmark and Neonatal Mortality Among Infants Weighing Sofie Biering-Sørensen  1   2 , Peter Aaby  2 , Najaaraq Lund  1   2 , Ivan Monteiro  2 , Kristoffer Jarlov Jensen  1   3 , Helle Brander Eriksen  1   2 , Frederik Schaltz-Buchholzer  2 , Anne Sofie Pinstrup Jørgensen  2 , Amabelia Rodrigues  2 , Ane Bærent Fisker  1   2 , Christine Stabell Benn  1   4 Affiliations Expand Affiliations 1 Research Center for Vitamins & Vaccines, Bandim Health Project, Statens Serum Institut, Copenhagen, Denmark. 2 Projécto de Saúde Bandim, INDEPTH Network, Bissau, Guinea-Bissau. 3 Department of Immunology and Vaccinology, National Veterinary Institute, Technical University of Denmark, Frederiksberg and. 4 Odense Patient Data Explorative Network, Institute of Clinical Research, University of Southern Denmark/Odense University Hospital, Denmark. PMID: 29579158 PMCID: PMC5849087 DOI: 10.1093/cid/cix525 Free PMC article Item in Clipboard

Sofie Biering-Sørensen, Peter Aaby, Najaaraq Lund, Ivan Monteiro, Kristoffer Jarlov Jensen, Helle Brander Eriksen, Frederik Schaltz-Buchholzer, Anne Sofie Pinstrup Jørgensen, Amabelia Rodrigues, Ane Bærent Fisker, Christine Stabell Benn, Sofie Biering-Sørensen, Peter Aaby, Najaaraq Lund, Ivan Monteiro, Kristoffer Jarlov Jensen, Helle Brander Eriksen, Frederik Schaltz-Buchholzer, Anne Sofie Pinstrup Jørgensen, Amabelia Rodrigues, Ane Bærent Fisker, Christine Stabell Benn

Abstract

Background: BCG vaccine may reduce overall mortality by increasing resistance to nontuberculosis infections. In 2 randomized trials in Guinea-Bissau of early BCG-Denmark (Statens Serum Institut) given to low-weight (LW) neonates (<2500 g at inclusion) to reduce infant mortality rates, we observed a very beneficial effect in the neonatal period. We therefore conducted the present trial to test whether early BCG-Denmark reduces neonatal mortality by 45%. We also conducted a meta-analysis of the 3 BCG-Denmark trials.

Methods: In 2008-2013, we randomized LW neonates to "early BCG-Denmark" (intervention group; n = 2083) or "control" (local policy for LW and no BCG-Denmark; n = 2089) at discharge from the maternity ward or at first contact with the health center. The infants were randomized (1:1) without blinding in blocks of 24. Data was analyzed in Cox hazards models providing mortality rate ratios (MRRs). We had prespecified an analysis censoring follow-up at oral poliovirus vaccine campaigns.

Results: Early administration of BCG-Denmark was associated with a nonsignificant reduction in neonatal mortality rate (MRR, 0.70; 95% confidence interval [CI], .47-1.04) and a 34% reduction (0.66; .44-1.00) when censoring for oral poliovirus vaccine campaigns. There was no reduction in mortality rate for noninfectious diseases, but a 43% reduction in infectious disease mortality rate (MRR, 0.57; 95% CI, .35-.93). A meta-analysis of 3 BCG trials showed that early BCG-Denmark reduced mortality by 38% (MRR, 0.62; 95% CI, .46-.83) within the neonatal period and 16% (0.84; .71-1.00) by age 12 months.

Conclusion: Early administration of BCG-Denmark in LW infants is associated with major reductions in mortality rate. It is important that all LW infants receive early BCG in areas with high neonatal mortality rates.

Clinical trials registration: NCT00625482.

Figures

Figure 1.
Figure 1.
Flowchart for the neonatal period (first 28 days of life). The “loss to follow-up” category denotes infants who could not be followed up because their mothers left the hospital without the field assistant and their residence was unknown. The “censored for other reasons” category denotes infants who had been included twice and were excluded on the second inclusion.
Figure 2.
Figure 2.
Cumulative mortality curves during the neonatal (28 days) and infant (365 days) periods according to randomization group. (Note differences in scale for the 2 curves.)
Figure 3.
Figure 3.
Mortality rates and mortality rate ratios (MRRs) in the 3 trials of early BCG vaccination of low-weight infants in Guinea-Bissau, by trial and combined in a meta-analysis (fixed effect model) with and without censoring for participation in oral poliovirus vaccine (OPV) campaigns. MRRs are given with 95% CIs. Trial I is the small randomized controlled trial (RCT) conducted in Guinea-Bissau in 2002–2004 (n = 104; median age at randomization, 2 days for early BCG and 4 days for controls) [8]; trial II, the RCT conducted in Guinea-Bissau in 2004–2008 (n = 2320) [7]; and trial III, the RCT conducted in Guinea-Bissau in 2008–2013 and presented in the current article (n = 4120; median age at randomization, 2 days for both early BCG and controls). Note differences in scale for the three panels.

References

    1. Shann F. Nonspecific effects of vaccines and the reduction of mortality in children. Clin Ther 2013; 35:109–14.
    1. Kristensen I, Aaby P, Jensen H. Routine vaccinations and child survival: follow up study in Guinea-Bissau, West Africa. BMJ 2000; 321:1435–8.
    1. Garly ML, Martins CL, Balé C et al. . BCG scar and positive tuberculin reaction associated with reduced child mortality in West Africa: a non-specific beneficial effect of BCG? Vaccine 2003; 21:2782–90.
    1. Roth A, Gustafson P, Nhaga A et al. . BCG vaccination scar associated with better childhood survival in Guinea-Bissau. Int J Epidemiol 2005; 34: 540–7.
    1. Roth A, Sodemann M, Jensen H et al. . Tuberculin reaction, BCG scar, and lower female mortality. Epidemiology 2006; 17: 562–8.
    1. Roth A, Jensen H, Garly ML et al. . Low birth weight infants and Calmette-Guérin bacillus vaccination at birth: community study from Guinea-Bissau. Pediatr Infect Dis J 2004; 23:544–50.
    1. Aaby P, Roth A, Ravn H et al. . Randomized trial of BCG vaccination at birth to low-birth-weight children: beneficial nonspecific effects in the neonatal period? J Infect Dis 2011; 204:245–52.
    1. Biering-Sørensen S, Aaby P, Napirna BM et al. . Small randomized trial among low-birth-weight children receiving bacillus Calmette-Guérin vaccination at first health center contact. Pediatr Infect Dis J 2012; 31:306–8.
    1. Higgins JP, Weiser KS, Reingold A.. Systematic review of the non specific effects of BCG, DTP and measles containing vaccines. Geneva, Switzerland: World Health Organization, 2014.
    1. World Health Organization. BCG vaccine: WHO position paper. Wkly Epidemiol Rec 2004; 4: 25–40.
    1. Benn CS, Diness BR, Roth A et al. . Effect of 50000 IU vitamin A given with BCG vaccine on mortality in infants in Guinea-Bissau: randomised placebo controlled trial. BMJ 2008; 336:1416–20.
    1. Benn CS, Fisker AB, Napirna BM et al. . Vitamin A supplementation and BCG vaccination at birth in low birthweight neonates: two by two factorial randomised controlled trial. BMJ 2010; 340:c1101.
    1. Lund N, Biering-Sørensen S, Andersen A et al. . Neonatal vitamin A supplementation associated with a cluster of deaths and poor early growth in a randomised trial among low-birth-weight boys of vitamin A versus oral polio vaccine at birth. BMC Pediatr 2014; 14:214.
    1. Ballard JL, Khoury JC, Wedig K, Wang L, Eilers-Walsman BL, Lipp R. New Ballard score, expanded to include extremely premature infants. J Pediatr 1991; 119:417–23.
    1. Byberg S, Benn CB. Placebo use in vaccine trials: caution when using active vaccines as placebo. Vaccine 2017; 35:1211.
    1. INDEPTH network. INDEPTH standardized verbal autopsy questionnaire Available at: . Accessed 7 July 2017.
    1. Behr MA. BCG—different strains, different vaccines? Lancet Infect Dis 2002; 2:86–92.
    1. Anderson EJ, Webb EL, Mawa PA et al. . The influence of BCG vaccine strain on mycobacteria-specific and non-specific immune responses in a prospective cohort of infants in Uganda. Vaccine 2012; 30:2083–9.
    1. Ritz N, Dutta B, Donath S et al. . The influence of bacille Calmette-Guerin vaccine strain on the immune response against tuberculosis: a randomized trial. Am J Respir Crit Care Med 2012; 185:213–22.
    1. Brosch R, Gordon SV, Garnier T et al. . Genome plasticity of BCG and impact on vaccine efficacy. Proc Natl Acad Sci U S A 2007; 104: 5596–601.
    1. Liu J, Tran V, Leung AS, Alexander DC, Zhu B. BCG vaccines: their mechanisms of attenuation and impact on safety and protective efficacy. Hum Vaccin 2009; 5:70–8.
    1. Bedwell J, Kairo SK, Behr MA, Bygraves JA. Identification of substrains of BCG vaccine using multiplex PCR. Vaccine 2001; 19:2146–51.
    1. Stensballe LG, Sørup S, Aaby P et al. . BCG vaccination at birth and early childhood hospitalisation: a randomised clinical multicentre trial. Arch Dis Child 2017; 102:224–31.
    1. Mawa PA, Nkurunungi G, Egesa M et al. . The impact of maternal infection with Mycobacterium tuberculosis on the infant response to bacille Calmette-Guerin immunization. Philos Trans R Soc Lond B Biol Sci 2015 June 19; 370(1671). doi:10.1098/rstb.2014.0137.
    1. Mawa PA, Webb EL, Filali-Mouhim A et al. . Maternal BCG scar is associated with increased infant proinflammatory immune responses. Vaccine 2017; 35:273–82.
    1. Haahr S, Michelsen SW, Andersson M et al. . Non-specific effects of BCG vaccination on morbidity among children in Greenland: a population-based cohort study. Int J Epidemiol 2016: 1–9.
    1. Benn CS, Sørup S. Commentary: BCG has no beneficial non-specific effects on Greenland. An answer to the wrong question? Int J Epidemiol 2016; 45:2131–3.
    1. Lund N, Andersen A, Hansen AS et al. . The effect of oral polio vaccine at birth on infant mortality: a randomized trial. Clin Infect Dis 2015; 61:1504–11.
    1. Kirkwood BR, Manu A, ten Asbroek AH et al. . Effect of the Newhints home-visits intervention on neonatal mortality rate and care practices in Ghana: a cluster randomised controlled trial. Lancet 2013; 381:2184–92.
    1. Ota MO, Vekemans J, Schlegel-Haueter SE et al. . Influence of Mycobacterium bovis bacillus Calmette-Guérin on antibody and cytokine responses to human neonatal vaccination. J Immunol 2002; 168:919–25.
    1. Kleinnijenhuis J, Quintin J, Preijers F et al. . Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc Natl Acad Sci U S A 2012; 109:17537–42.
    1. Netea MG, Quintin J, van der Meer JW. Trained immunity: a memory for innate host defense. Cell Host Microbe 2011; 9:355–61.
    1. Kleinnijenhuis J, Quintin J, Preijers F et al. . Long-lasting effects of BCG vaccination on both heterologous Th1/Th17 responses and innate trained immunity. J Innate Immun 2014; 6:152–8.
    1. Jensen KJ, Larsen N, Biering-Sørensen S et al. . Heterologous immunological effects of early BCG vaccination in low-birth-weight infants in Guinea-Bissau: a randomized-controlled trial. J Infect Dis 2015; 211:956–67.
    1. Clark A, Sanderson C. Timing of children’s vaccinations in 45 low-income and middle-income countries: an analysis of survey data. Lancet 2009; 373:1543–9.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel